Article Text

Download PDFPDF

Orlistat with diet was effective and safe for weight loss and coronary risk reduction in obesity

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: What is the effectiveness of orlistat for weight loss and coronary artery disease risk factor reduction in people who are obese and have ≥1 coronary risk factor?


Randomised (unclear allocation concealment*), blinded (patients, outcome assessors),* placebo controlled trial with 1 year follow up.


33 primary care centres in Sweden.


376 patients between 18 and 75 years of age (mean age 53 y, 64% women) who had a body mass index between 28 and 38 kg/m2. Patients had to have ≥1 of the following: fasting serum glucose concentration ≥6.7 mmol/l or type-2 diabetes mellitus treated with sulfonylurea or metformin (not insulin); cholesterol concentration ≥6.5 mmol/l or low density lipoprotein (LDL) cholesterol concentration ≥4.2 mmol/l on ≥2 occasions, or lipid lowering medication; or diastolic blood pressure concentration ≥90 mm Hg on ≥2 …

View Full Text